369 PENTRAXIN 3 AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF ACTIVE MYOCARDITIS
نویسندگان
چکیده
Abstract Background Pentraxin 3 (PTX3) is an acute phase protein, which regulates the outcomes of inflammation. Currently, there are no myocarditis-typical biomarkers that allow a non-invasive diagnosis, and endomyocardial biopsy (EMB) still gold standard. Finally, risk stratification often challenging in these patients. Aim To investigate whether PTX3 could be expressed cardiomyocytes released during myocarditis, serving as novel independent diagnostic indicator myocardial inflammation, contributing to prognosis prediction. Methods Fifty-five patients with diagnosis or chronic active myocarditis proven by cardiac magnetic resonance (CMR) and/or (EMB), were included. First, we evaluated tissue expression immunohistochemistry (IHC). Then, assessed circulating blood ELISA technique. Results On tissue, at IHC did not localize interstitium, showed inconstant vascular endothelium, but marked staining all The only exception was represented two systemic COVID-19, SARS-CoV-2 PVB-19 intracardiac genomes, respectively, who diffuse expression. Remarkably, semi-quantitative pixel analysis, viral aetiology higher levels expression, rather than autoimmune one. Circulating significantly controls, pathologic values 87% patients, none among controls. plasma proved more sensitive detection CRP, ESR, troponin T, NT-proBNP. As regards prognosis, observed heart failure (HF) presentation had elevated levels, compared chest pain arrhythmia. reduced LVEF (<50%) admission recovered follow-up baseline those whose systolic function improve. Conclusions Tissue mostly on EMB samples. In addition, prognostic marker inflammatory cardiomyopathy.
منابع مشابه
C-reactive protein as a prognostic marker in lymphocytic myocarditis.
The prognosis of patients with lymphocytic myocarditis (LM) is poor with the combined endpoint of death or transplant in the Myocarditis Treatment trial being 56% at 5 years. Physicians often have difficulty determining the prognosis in an individual patient. Patients with LM may have ongoing myocardial inflammation. We evaluated the ability of a serum marker of inflammation to predict prognosi...
متن کاملPentraxin 3 as a Novel Marker in Cardiovascular Diseases?
Pentraxin 3 (also known as TNFAIP5, TSG-14) belongs to the superfamily of proteins characterized by cyclic multimeric structure. Pentraxin 3 (PTX3) is synthesized locally at the inflammatory sites by endothelial and smooth muscle cells upon exposure to inflammatory signals such as IL-1β, TNF-α or ox-LDL, but not IL-6. Furthermore, PTX3 is highly expressed in vascular cells and myocardial cells ...
متن کاملbiotinidase, as a convenient diagnostic and prognostic marker for breast cancer
according to the definition by the national institutes of health of usa, a biological marker (biomarker) is a characteristic that is objectively measured and evaluated, as an indicator of normal biological processes, pathogenic processes or pharmacological responses, to a therapeutic agent. several studies have reported that a decreased regulating gene expression of biotinidase (btd) is associa...
متن کاملPentraxin-3 as a Marker of Advanced Atherosclerosis Results from the Bruneck, ARMY and ARFY Studies
OBJECTIVE Pentraxins like C-reactive protein are key components of the innate immune system. Recently, pentraxin-3 (PTX3) has been proposed to be a specific marker of vascular inflammation, yet its association with atherosclerosis is still unclear. METHODS AND RESULTS PTX3 serum levels were measured in three independent studies of 132 young men (ARMY Study), 205 young women (ARFY Study) and 5...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal Supplements
سال: 2022
ISSN: ['1520-765X', '1554-2815']
DOI: https://doi.org/10.1093/eurheartjsupp/suac121.683